Stoke Therapeutics (STU:0GT) ROCE % : -23.68% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Stoke Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2024 was -23.68%.

Stoke Therapeutics ROCE % Historical Data

The historical data trend for Stoke Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics ROCE % Chart

Stoke Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-19.92

-35.28

-48.25

-53.53

-48.14

Stoke Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-56.77	-61.94	-54.44	-46.62	-23.68

Stoke Therapeutics ROCE % Calculation

Stoke Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-96.81	/	( ( (209.39 - 28.261)	+	(259.335 - 38.253) )	/ 2 )
	=	-96.81	/	( (181.129	+	221.082)	/ 2 )
	=	-96.81	/	201.1055
	=	-48.14 %

Stoke Therapeutics's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-52.156	/	( ( (264.28 - 44.928)	+	(259.335 - 38.253) )	/ 2 )
	=	-52.156	/	( ( 219.352	+	221.082 )	/ 2 )
	=	-52.156	/	220.217
	=	-23.68 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Stoke Therapeutics (STU:0GT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Stoke Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Stoke Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Stoke Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (STU:0GT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

STOK:USA 0GT:Germany

Address

45 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.stoketherapeutics.com

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Stoke Therapeutics Headlines

No Headlines